Iron overload treatment leads Shire to acquire FerroKin

03/15/2012 | Fox Business · Xconomy

FerroKin's lead drug candidate, FBS0701, is in midstage clinical trials to treat iron overload in people who have received multiple blood transfusions. Shire said it will buy the biotech firm as part of an effort to expand its hematology business. Shire agreed to pay $100 million in cash, plus as much as $225 million in milestone payments.

View Full Article in:

Fox Business · Xconomy

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President - Government Products
Health Alliance Plan
Detroit, MI
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Actuary
Meridian Health Plan
Detroit, MI
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
President/Chief Executive Officer
MedCost
Winston-Salem, NC